Get our lovely INSIGHT 2019 conference news

Email address
First Name
Last Name
Interested in InSight 2019

What are you looking for?

<Good_things_happen/> Welcome to Conference

A new approach to treating depression; a non-profit’s role in advancing the science and regulatory path to approval for psilocybin

Depression is the leading cause of disability worldwide, affecting more than 300 million people, according to the World Health Organization. It can reduce life expectancies by an average of 10 years and may lead to suicide from which nearly 800,000 people die each year. There is an urgent need to identify and test novel treatments that may benefit people suffering from depression.
A series of academic studies have shown that a single high dose of the psilocybin produces a rapid and durable reduction in depression — even in patients who have failed currently approved antidepressants. Like other psychedelics, the pharmacological profile of psilocybin is novel and the nature of its clinical activity represents a new paradigm in the treatment of mental illness.

Usona Institute, a 501(c)3 nonprofit Medical Research Organization based in Madison, Wisconsin, USA, was founded  in 2014 for the purpose of moving the highly encouraging early-phase psilocybin studies at UCLA, Johns Hopkins, and New York University, and others through the necessary phases of FDA-regulated clinical trials with the aim of an FDA new drug approval. Usona’s first psilocybin clinical trial will begin in late 2019, and will examine the safety and efficacy of psilocybin for the treatment of major depressive disorder (MDD).
In this presentation, Dr. Charles Raison will discuss the unmet medical need in depression treatment, the results of promising academic studies to date, and Usona’s unique role in sponsoring FDA-regulated clinical trials as a nonprofit medical research entity following an Open Science approach to research and drug development.



September 6th 2019




Charles L. Raison

Charles L. Raison

Professor, School of Human Ecology, and Professor, Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison more about the speaker

Related Events

Therapeutic Effects of Psilocybin

For over 15 years the Johns Hopkins Psychedelic Group has been the preeminent and most productive research team in the United States conducting human research with psychedelics...

more details

Integration Psychotherapy

This talk will focus on Psychedelic Integration in a clinical setting...

more details

The Re-Evaluation of Psychedelics: Challenges for Science, Therapy and Public Health

Do psilocybin, LSD and MDMA finally gain medical significance? Dr. Henrik Jungaberle will provide data and concepts that support changes in common misrepresentations about psychedelic states, therapies and their benefit-risk ratio.

more details

Current Research on LSD in Healthy Subjects and Patients

Lysergic acid diethylamide (LSD) is used in Switzerland in the treatment of patients both in the context of compassionate use and in clinical studies including patients with anxiety associated with life-threatening diseases...

more details

Conference tickets

With your ticket you will have access to the whole conference - with keynotes, panels, round tables, posters and daylight social events. We will ask for a small extra fee for the Friday evening social program. The pre-conference workshops have to be booked separately and each workshop needs an individual ticket. By clicking on "Book now" below you also have the option to buy your workshop tickets.

*Reduced fees apply to students, cooperation partners as well as unemployed and retired individuals who have a monthly net income below 840,- €. Proof of status will be required.

THE CONFERENCE IS SOLD OUT! Subscribe to our newsletter to become an early bird for 2021!

Get our lovely INSIGHT 2019 conference news

Email address
First Name
Last Name